Document is current
Any future updates will be listed below
-
Authors
Agrawal, Rupesh http://orcid.org/0000-0002-6662-5850
Ludi, Zhang
Betzler, Bjorn K. http://orcid.org/0000-0002-4843-7514
Testi, Ilaria
Mahajan, Sarakshi
Rousellot, Andres http://orcid.org/0000-0003-2341-0988
Kempen, John H. http://orcid.org/0000-0002-2967-4792
Smith, Justine R.
McCluskey, Peter
Nguyen, Quan Dong http://orcid.org/0000-0002-6024-8441
Pavesio, Carlos
Gupta, Vishali
- License Information
-
More Information
Article History
Received: 4 March 2022
Revised: 15 May 2022
Accepted: 14 June 2022
First Online: 28 June 2022
Competing interests
: RA, ZL, BB, IT, SM, AR, JHK, JRS, PM, QDN, CP and VG report no competing interests, financial or propriety, in the subject matter or materials discussed in this paper. JHK is a consultant for Gilead Pharma, a company evaluating a treatment for non-infectious uveitis, and equity owner for Betaliq, a company developing an intraocular pressure-lowering treatment. RA is supported by a grant from the National Medical Research Council (NMRC) by Ministry of Health, Singapore, for the Clinician Scientist Award (CSA) from 2020 to 2023. He has not received funding for his work in this publication.
